Tesamorelin Recommended for body recomposition Pros Has been shown to selectively reduce abdominal fat in patients with HIV Can also increase muscle area and strength Promising implications for cognitive and cardiovascular health No reported risk of immunogenicity Cons Studies so far have focused on patients with HIV May cause flu-like symptoms Usually administered by subcutaneous injection Prohibited by the World Anti-Doping Agency Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy excess abdominal lipid accumulation as a result of antiretroviral therapy its efficacy against which was evidenced in a 2010 clinical trial that demonstrated an 18% decrease in visceral fat in intervention subjects compared to placebo.11 Concerning muscle growth, a later study of HIV patients determined that tesamorelin was effective in increasing skeletal muscle area and density.28 Also, because visceral fat is associated with increased cardiovascular mortality, tesamorelin exhibits promise as a treatment for serious health conditions like heart disease and stroke.37 Although tesamorelin studies so far have understandably centered on patients with HIV, theory holds that the peptide should have the same effects on other users
[2] Second, in cultured dermal microvascular and fibroblast models, GHK-Cu exposure has been associated with increased vascular endothelial growth factor expression, a change that could enhance perifollicular microcirculation
Injectable peptide products are a separate category with different oversight
In addition, by using AlzDatas Differential Expression module, the normalized expression of targets of FRP against AD in control and AD groups of the GEO dataset were analyzed
Quality is central to every Research Peptide we manufacture
A peer-reviewed study in the Journal of Cosmetic Dermatology found GHK-Cu reduced wrinkle volume by 55.8% and outperformed Matrixyl 3000 by 31.6% in wrinkle volume reduction
